쉐도잉 연습: Medium Vessel Occlusion: Should We Thrombectomize? - 영상으로 영어 말하기 배우기
연습 모드 선택
각 모드는 전체 화면 연습실로 열립니다.
120 문장
문장이 너무 짧거나 길면 Edit를 눌러 조정하세요.
1
Hello everyone, my name is Puriya Moshaydi.
2
I'm a vascular neurologist and neurointerventionist at Tehran University of Medical Sciences.
3
I'm very honored to be invited on this panel discussing thrombectomies in medium vessel occlusions.
4
Should we still treat them?
5
And my take is we should not.
6
I have no conflict of interest and speaking in front of a group of neurodeterventionists and say that do not do thrombectomy,
7
giving me a feeling that is best depicted in this slide, how I divide roles between myself and Dr. Al -Rahimi.
8
So let's first start with talking what is a medium vessel.
9
So we know what large vessel is.
10
Large vessel are basilar arteries, internal carotides, and the main branch of middle cerebral artery.
11
And anything beyond that is considered middle vessel,
12
medium vessel, including PCAs, ACAs, and MCA branches, M2s.
13
There are some nuances.
14
We know that there is an anatomic variability on how M2s are branching.
15
The main application here is sometimes you have a dominant M2s that you see here.
16
one m2 is bigger than the other one
17
and sometimes you have co -dominant m2s and obviously a non -dominant m2
18
so a dominant m2 is actually a large vessel occlusion as they have been included in other lvo trials
19
and non -dominant or co -dominant m2s are in fact medium vessels
20
and the medium vessel occlusion trials published so far include all the medium vessels but majority are m2s so let's
21
take a step back.
22
When Dawn trials were underway and it was published, I was a resident at UPMC, we often had this discussion with my mentor,
23
Tudor Joven, who would argue astonishing number needed to treat of two for any improvement after thrombectomy,
24
any functional outcome improvement at 90 days may indicate that we own a very effective treatment,
25
but may also show that we are being very over selective in a group of patients,
26
meaning that we are able to exclude any patient with lesser likelihood of benefiting from thrombectomy.
27
And so we usually select patients based on the loss known normal, degree of disability, the location of occlusion, and the infarct volume.
28
And so the next generation of trials, which the MEVO trials belong to them, is starting to testing those boundaries.
29
So going beyond the time limits,
30
the publication by my very good friend Shashva Desai showed that if you select patients that are in the
31
DAWN criteria would be included, except the time of onset, even going as far as 72 hours, they would have the same benefit as patients in DAWN.
32
So they successfully crossed the time limit although it's not within our guidelines yet
33
and then we're all aware of the large core trials uh this is the one by dr saraj
34
that the number needed to treat drop from 2 .1 to 7 .7
35
but they still show the benefit for thrombectomies but
36
so the second line was crossed successfully
37
but are we able to go from large vessel thrombectomy to medium vessel thrombectomy And even before starting the trials, was it expected to help?
38
So let's look at the subgroup analysis of the early time point thrombectomy trials and the Hermes meta -analysis.
39
So I want to draw your attention in the subgroup of M2s, which were included in some of those five trials.
40
the subgroup of M2s actually did not benefit from thrombectomy.
41
And also those that their NIH stress scale was less than 10.
42
So the myelore stroke symptoms.
43
And this is important because actually looking at the patients with medium vessel occlusions,
44
the presenting NIH stress scales is an average three points below large vessel occlusion.
45
So you're dealing with a less disabled group of patients, let's call it.
46
And then looking at the subgroup analysis of late -time window EVT, this is from diffuse tree, the same thing showed up.
47
So the subgroup of patients with milder NISOS scale, again, they did not benefit from thrombectomy.
48
So this is how we entered, um, the the information we have before doing the medium vessel occlusion trials
49
and there were some studies on the PCAs and ACA showing
50
that ACA thrombectomy would not change the outcome they were non -randomized
51
but still I think they're worth mentioning
52
and then there was a observational study on PCA thrombectomies
53
that in fact it showed that thrombectomy we call a higher rate of symptomatic ICH and a worse recovery.
54
So this is how we entered.
55
So I want to use this nice picture from the publication by Goldberg and colleagues.
56
We have two published trials, Distal and Escape MVO and Discount, which is not yet published.
57
Correct me if I'm wrong.
58
This is the baseline studies.
59
So what I want to draw your attention to is
60
that each study was enough powered and And they were trying patients with different time points, less than 12 hours, less than 24 hours, less than 8 hours.
61
And they were also variable and allowed different devices to be used.
62
Some obliged the operator to use the stent retriever, some gave them flexibility.
63
So the results that would come from these trials will have generalizability to different times of onset and different device usage.
64
The outcome, again, this is part of the baseline characteristics.
65
You would see that in all the trials, both discount distal and SCAPE -MEVO,
66
the patients that were included as expected they were presented with mylar stroke symptoms
67
so you are doing a procedure on a patient
68
that is much less disabled remember the the average of patient in dawn were
69
about five or six units higher in an NHSRO scale and then the symptomatic ICH in all the trials
70
were really considerable and discounted with 12 percent in distal was 5 .9 percent
71
and 5 .4 percent in escape mevo
72
and then I want to again compare it with the meta -analysis of large vessel occlusion thrombectomies
73
that the symptomatic ICH were only 4 .4 percent so you are treating a patient
74
treating group of patients with milder symptoms with a more risky procedure.
75
So have this in mind.
76
And then in terms of outcomes, so we have the escape mevo and distal,
77
which showed no benefit in outcome at 90 days.
78
As you see, the confidence interval will cross the value one,
79
and the escape mevo in fact showed a higher rate of 90 days mortality
80
which was significant in interventional group so it shows
81
that we're not only benefiting but we are at some point harming
82
so one word of caution that discount results which were preliminary presented in isc
83
it showed that there was a significant improvement in thrombectomy patients for the MRC score equal less than 2 at 90 days.
84
But this was this annotation at the bottom after multiple imputation of missing data.
85
So I don't know what it means.
86
I don't know what it would turn into when it comes out as a full paper.
87
So we have to look out for it.
88
So we are talking about the thrombectomy in a group of patients or in one patient they are facing.
89
You're doing thrombectomy in a patient which has milder symptoms in a risky procedure.
90
But I want to also take this discussion into a global health level.
91
So this is the picture from MT Glasses study,
92
mission thrombectomy, which shows the access of different countries to thrombectomies.
93
As you can see, even the good countries are colored in green, only about a third of patients eligible for thrombectomy have access to it.
94
The situation for other countries is dismal.
95
Majority of MENA countries have less than 10 % access to thrombectomies.
96
So what I'm feeling that as neurointerventionists, although we have the duty to bring the best for our patient,
97
but it seems that we have a more pressing and urgent challenge, meaning that
98
improving access to thrombectomies for large vessel occlusion you know we are living in a world
99
that the resources are limited
100
so we can invest in finer devices for middle vessel occlusion thrombectomies as we we saw
101
that the thrombectomies in this population is more risky
102
so maybe we can already our devices is not uh prepared for it
103
but we can also invest that time and effort and money in making LVO device thrombectomies more available.
104
And that is the subject of grassroots trials,
105
bringing a stent retriever in with the lesser cost so that it could widen its coverage.
106
It actually came out from the Mission Thrombectomy Initiative.
107
And I think it got approval in India, if I'm not wrong, it got approval in Thailand before it.
108
So, So as an interventionist, when I'm facing the MEVO study,
109
we can talk about like different pieces of information that we have.
110
That for MEVO, we are treating patients with milder symptoms.
111
Our procedure is more risky, causing higher degree of symptomatic ICH, even mortality.
112
We have less successful reperfusion and no proven functional outcome.
113
But I think as a next step, if I have a choice of going after improving the devices
114
and refining trials for smaller vessels or trying to widen the very dismal global coverage for mechanical thrombectomy for LVO,
115
I would definitely choose the second one.
116
So, my answer to doing thrombectomies in medium vessel occlusions is no,
117
then I'm leaving a stage to my very good colleague, Dr. Rohini.
118
This is a picture of Tehran from the hospital that I work with.
119
Hopefully, we can all meet there.
120
And thank you for your attention.
앱 다운로드
유창하게 말하는 데 필요한 모든 것
AI 발음 평가문장마다 점수 확인
IPA 발음 연습모든 소리 마스터
단어 학습나만의 단어장 만들기
단어 게임놀면서 외우기
FOR YOU
추천 영상
이 레슨의 어휘와 말하기 포인트
이 영상에는 섀도잉할 문장 120개와 단어 1578개가 있습니다. 말하는 구간의 길이는 12:00입니다. 화자는 분당 약 132단어의 일정한 속도로 말해서 섀도잉하기에 편한 속도입니다. 영어에서 가장 많이 쓰이는 3,000단어에 속하는 단어가 76%뿐이라 어휘가 어려운 편입니다.
이 영상의 핵심 어휘
영상에 나오는 익혀 둘 만한 단어 15개를 발음, 뜻과 함께 정리했습니다.
| 단어 | 발음 | 뜻 |
|---|---|---|
| vessel 명사 | /ˈvɛsəl/ | 배, 선박 |
| symptom 명사 | /ˈsɪm(p)təm/ | 증상, 증후 |
| procedure 명사 | /pɹəˈsiː.d͡ʒə/ | 절차, 수단 |
| discount 명사 | /ˈdɪskaʊnt/ | 할인 |
| dawn 명사 | /dɔːn/ | 새벽 |
| mild 형용사 | /ˈmaɪld/ | 온화한 |
| risky 형용사 | /ˈɹɪski/ | 위험한 |
| publication 명사 | /ˌpʌblɪˈkeɪʃ(ə)n/ | 출판, 간행 |
| select 동사 | /sɪˈlɛkt/ | 고르다 |
| colleague 명사 | /ˈkɒliːɡ/ | 동료, 동업자 |
| mortality 명사 | /mɔɹˈtælɪti/ | 사망 |
| onset 명사 | /ˈɒnˌsɛt/ | 음절초 |
| artery 명사 | /ˈɑɹ.təɹ.i/ | 동맥 |
| harm 명사 | /hɑːm/ | 해 |
| argue 동사 | /ˈɑɹ.ɡju/ | 논하다, 의논하다 |
영상에 나오는 구동사
| 단어 | 발음 | 뜻 |
|---|---|---|
| come out 동사 | /ˌkʌm ˈaʊt/ | 나오다 |
이 영상의 문법
화자가 가장 많이 쓰는 문형을 영상 속 실제 표현과 함께 정리했습니다.
| 문형 | 영상 속 표현 |
|---|---|
| 수동태 be + 과거분사 — 누가 하는지보다 무슨 일이 일어나는지에 초점 | be invited · is considered · have been included |
| 관계절 who / which + 절 — 사람이나 사물에 대한 추가 정보 | Discount, which is · results which were · patient which has |
주의할 발음
화자는 I'm, don't, we're 같은 축약형과 약화된 형태를 14번 사용합니다. 들리는 대로 짧게 발음하세요.
- “sh”와 “zh” 소리: publication /ˌpʌblɪˈkeɪʃ(ə)n/, caution /ˈkɔːʃ(ə)n/, occlusion /əˈkluː.ʒən/, annotation /ˌæn.əˈteɪ.ʃən/, astonish /əˈstɑnɪʃ/
- 긴 단어 — 강세 위치에 주의: publication /ˌpʌblɪˈkeɪʃ(ə)n/, successfully /səkˈsɛs.fə.li/, mortality /mɔɹˈtælɪti/, mechanical /məˈkænəkəl/, operator /ˈɑpəˌɹeɪtɚ/
이 영상으로 연습하는 방법
- 먼저 말하지 않고 영상을 끝까지 듣고 모르는 단어를 적어 둡니다.
- 보통 속도로 한 문장씩 섀도잉하고, 화자의 리듬과 맞을 때까지 반복합니다.
- 자신의 목소리를 녹음해 원본과 비교하고, vessel, symptom, procedure 같은 단어에 특히 주의합니다.
쉐도잉이란? 영어 실력을 빠르게 키우는 과학적 방법
쉐도잉(Shadowing)은 원래 전문 통역사 훈련을 위해 개발된 언어 학습 기법으로, 다언어 학자인 Dr. Alexander Arguelles에 의해 대중화된 방법입니다. 핵심 원리는 간단하지만 매우 강력합니다: 원어민의 영어를 들으면서 1~2초의 짧은 지연으로 즉시 소리 내어 따라 말하는 것——마치 '그림자(shadow)'처럼 화자를 따라가는 것입니다. 문법 공부나 수동적인 청취와 달리, 쉐도잉은 뇌와 입 근육이 동시에 실시간으로 영어를 처리하고 재현하도록 훈련합니다. 연구에 따르면 이 방법은 발음 정확도, 억양, 리듬, 연음, 청취력, 말하기 유창성을 크게 향상시킵니다. IELTS 스피킹 준비와 자연스러운 영어 소통을 원하는 분들에게 특히 효과적입니다.












